← The Wire
ELVNNasdaq
Enliven Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1672619
Develops small molecule therapeutics targeting cancer-driving genes like BCR-ABL and HER2
$2.81B
Market cap
$50.85
Last close
+1.5%
1D
+10.6%
5D
1.6M
Volume
Price · last 39 sessions+22.2%
May 4L $33.63 · H $50.85Jun 29
134
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
SC 13D/ASC 13D/AJun 24, 2026SC 13D/ASC 13D/AJun 17, 20268-KMaterial Agreement · Reg FD DisclosureJun 12, 2026424B5424B5Jun 12, 2026424B5424B5Jun 11, 20268-KReg FD Disclosure · Company UpdateJun 11, 20268-KBylaw Amendment · Shareholder VoteJun 10, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 27, 2026DEF 14ADEF 14AApr 27, 202610-K10-KMar 3, 20268-KResults of OperationsMar 3, 20268-KExecutive ChangeJan 7, 20268-KExecutive Change · Reg FD DisclosureDec 11, 20258-K/AResults of OperationsNov 13, 202510-Q10-QNov 12, 20258-KResults of OperationsNov 12, 202510-Q10-QAug 13, 20258-KResults of OperationsAug 13, 20258-KShareholder VoteJun 25, 20258-KMaterial Agreement · Company UpdateJun 16, 2025424B5424B5Jun 16, 2025424B5424B5Jun 13, 20258-KReg FD Disclosure · Company UpdateJun 13, 202510-Q10-QMay 14, 20258-KResults of OperationsMay 14, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 202510-K10-KMar 13, 20258-KResults of OperationsMar 13, 2025SC 13GSC 13GNov 13, 202410-Q10-QNov 13, 20248-KResults of OperationsNov 13, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 24, 202410-Q10-QAug 13, 20248-KResults of OperationsAug 13, 20248-KExecutive Change · Bylaw AmendmentJun 18, 20248-K/AExecutive ChangeMay 29, 202410-Q10-QMay 14, 20248-KResults of OperationsMay 14, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KCompany UpdateApr 11, 20248-KExecutive ChangeApr 9, 20248-KMaterial Agreement · Equity IssuanceMar 19, 202410-K10-KMar 14, 20248-KResults of OperationsMar 14, 202410-Q10-QNov 9, 20238-KResults of OperationsNov 9, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 2023424B5424B5Jul 6, 20238-KMaterial Agreement · Agreement TerminatedJun 26, 20238-KShareholder Vote · Company UpdateJun 23, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 2023SC 13GSC 13GMay 10, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 2023SC 13GSC 13GApr 27, 2023SC 13GSC 13GApr 24, 20238-K/AReg FD Disclosure · Company UpdateMar 21, 2023SC 13GSC 13GMar 13, 2023SC 13GSC 13GMar 6, 2023SC 13DSC 13DMar 6, 20238-KAuditor Change · Change of ControlMar 1, 2023SC 13DSCHEDULE 13DFeb 28, 2023425425Feb 22, 20238-KExecutive Change · Security-Holder RightsFeb 22, 2023425425Feb 13, 20238-KCompany UpdateFeb 13, 202310-K10-KFeb 10, 2023425425Dec 5, 20228-KCompany UpdateDec 5, 20228-K/ACompany UpdateNov 16, 2022S-4S-4Nov 10, 20228-KAcquisition / Disposition · Shareholder VoteNov 10, 202210-Q10-QOct 25, 2022
Insider Activity
In the 90 days to Mar 25, 2026: 5 sold $10.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 40,000 | $35.10 | $1.4M |
| Mar 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 5,000 | $27.76 | $139K |
| Mar 10, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 10,129 | $30.19 | $306K |
| Mar 9, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 29,871 | $30.02 | $897K |
| Mar 6, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER | Sell | 10,000 | $29.58 | $296K |
| Feb 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Sell | 45,000 | $26.17 | $1.2M |
| Feb 17, 2026 | Heyman Richard A.Director | Sell | 1,230 | $26.18 | $32K |
| Feb 6, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $29.04 | $145K |
| Jan 20, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 14,509 | $26.90 | $390K |
| Jan 20, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 5,491 | $26.37 | $145K |
| Jan 20, 2026 | Heyman Richard A.Director | Sell | 718 | $26.96 | $19K |
| Jan 20, 2026 | Heyman Richard A.Director | Sell | 512 | $26.46 | $14K |
| Jan 9, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 50,000 | $29.13 | $1.5M |
| Jan 9, 2026 | Patel AnishCHIEF OPERATING OFFICER | Sell | 48,057 | $27.98 | $1.3M |
| Jan 9, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 41,198 | $24.90 | $1.0M |
| Jan 9, 2026 | Heyman Richard A.Director | Sell | 4,285 | $25.00 | $107K |
| Jan 9, 2026 | Patel AnishCHIEF OPERATING OFFICER | Sell | 243 | $28.50 | $7K |
| Jan 8, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 33,802 | $24.92 | $842K |
| Jan 8, 2026 | Heyman Richard A.Director | Sell | 8,015 | $25.04 | $201K |
| Jan 8, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | Sell | 7,500 | $20.13 | $151K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance